| Literature DB >> 22518349 |
Jooeun Song1, Susan Sigward, Beth Fisher, George J Salem.
Abstract
Persons with early-stage Parkinson's disease (EPD) do not typically experience marked functional deficits but may have difficulty with turning tasks. Studies evaluating turning have focused on individuals in advanced stages of the disease. The purpose of this study was to compare postural control strategies adopted during turning in persons with EPD to those used by healthy control (HC) subjects. Fifteen persons with EPD, diagnosed within 3 years, and 10 HC participated. Participants walked 4 meters and then turned 90°. Dynamic postural control was quantified as the distance between the center of pressure (COP) and the extrapolated center of mass (eCOM). Individuals with EPD demonstrated significantly shorter COP-eCOM distances compared to HC. These findings suggest that dynamic postural control during turning is altered even in the early stages of PD.Entities:
Year: 2012 PMID: 22518349 PMCID: PMC3306994 DOI: 10.1155/2012/386962
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Mean and standard deviation of participant's characteristics.
| Group | |||
|---|---|---|---|
| EPD ( | HC ( | Differences (95% CI) | |
| Age (yr) | 62 (9.1) | 60 (8.5) | 2 (−5.49; 9.49) |
| Height (m) | 1.68 (0.07) | 1.72 (0.09) | −0.04 (−0.11; 0.03) |
| Weight (kg) | 68.9 (12.1) | 74.8 (17.2) | −5.9 (−17.99; 6.19) |
| Approach gait velocity (m/s) | 1.35 (0.14) | 1.46 (0.14) | −0.11 (−0.23; 0.01) |
Mean (Standard Deviation).
EPD: persons with early-stage Parkinson's disease.
HC: healthy control participants.
Dosage of Parkinson's medications.
| Participant number | Medication | Dosage | Frequency |
|---|---|---|---|
| P01 | Levodopa/carbidopa | 25–100 mg | 3x/day |
| P02 | De Novo | ||
| P03 | Pramipexole | 1 mg | 3x/day |
| Rasagiline | 1 mg | 1x/day | |
| Levodopa/carbidopa | 50–200 mg | 3x/day | |
| P04 | De Novo | ||
| P05 | Pramipexole | 1.5 mg | 3x/day |
| Selegiline | 5 mg | 2x/day | |
| P06 | Rasagiline | 1 mg | 1x/day |
| Amantadine | 100 mg | 2x/day | |
| P07 | De Novo | ||
| P08 | Rasagiline | 1 mg | 1x/day |
| Trihexyphenidyl | 4 to 6 mg | 1x/day | |
| P09 | Levodopa/carbidopa | 150 mg | 3x/day |
| P10 | Pramipexole | 0.75 mg | 3x/day |
| Rasagiline | 1 mg | 1x/day | |
| P11 | Pramipexole | 1.5 mg | 3x/day |
| Rasagiline | 1 mg | 1x/day | |
| P12 | Levodopa/carbidopa | 25–100 mg | 4x/day |
| P13 | Levodopa/carbidopa | 25–100 mg | 3x/day |
| Rasagiline | 0.5 mg | 1x/day | |
| P14 | Pramipexole | 0.5 mg | 3x/day |
| P15 | Pramipexole | 1.5 mg | 3x/day |
| Selegiline | 5 mg | 2x/day | |
| Trihexyphenidyl | 2 mg | 3x/day |
Figure 1Laboratory setup. Dashed line: starting point; A: first trigger; B: second trigger; black square: force plate (AMTI 1.2 m × 1.2 m, 1560 Hz). Two stanchions were placed at the midpoint of each force plate. Starting point to A: 1 m. A to B: 2.4 m. B to force plate: 0.6 m. Force plate to stanchions: 0.6 m.
Figure 2Schematic representation of the COP and the eCOM trajectories during the step turn. Solid line: eCOM trajectory; dashed gray line: COP trajectory; Phase 1: from approach step to pivot step; Phase 2: from pivot step to acceleration step.
Figure 3Resultant COP-eCOM distance (a), and resultant COP-COG distance (b), resultant COM velocity (c) between groups during the step turn cycle (±sd). HS: heel strike; TO: toe off; light gray line: persons with early-stage Parkinson's disease; black line: healthy control participants; gray shadow: double limb support time; white shadow: single limb support time. †denotes statistically significant difference between groups (P < 0.05). *denotes statistically significant difference between phases (P < 0.05).